Socazolimab for first-line treatment of advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This phase 3 trial tests a new immunotherapy drug called socazolimab combined with chemotherapy as a first treatment for cervical cancer that has come back, spread, or cannot be removed with surgery or radiation. The goal is to see if it helps shrink tumors and improves survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between the ages of 18 and 75.
- You have cervical cancer that cannot be cured by surgery or radiation, or it has come back or spread.
- You have not had prior treatment with certain immunotherapies or anti-angiogenic drugs like bevacizumab.
- You are able to provide a sample of your tumor tissue (from a previous biopsy or a new one).
- You have good organ function as shown by blood tests and no active autoimmune disease or serious infections.
- You are not pregnant, plan to become pregnant, or breastfeed, and you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
This trial tests a new immunotherapy drug, serplulimab, for people with locally advanced cervical cancer. The goal is to see if it can help shrink or control the cancer before standard treatments.
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
This study tests a new combination of drugs for women with advanced cervical cancer that has not been previously treated. The goal is to see if the combination can shrink tumors or slow down the cancer, and to check its safety.
This trial tests whether giving chemotherapy combined with camrelizumab (a drug that helps the immune system fight cancer) before surgery can help women with early-stage cervical cancer who want to preserve their fertility. It is for patients whose tumors show a protein called PD-L1.
This trial tests adding a targeted drug called nimotuzumab to the standard chemoradiotherapy for cervical cancer, followed by ongoing maintenance treatment. It aims to see if this combination helps control the cancer better than chemoradiotherapy alone.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.